Dr Reddy's Laboratories ROE 2012-2025 | RDY
Current and historical return on equity (ROE) values for Dr Reddy's Laboratories (RDY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Dr Reddy's Laboratories ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-12-31 | $0.65B | $4.08B | 15.82% |
| 2025-09-30 | $0.68B | $3.98B | 17.05% |
| 2025-06-30 | $0.66B | $3.88B | 17.06% |
| 2025-03-31 | $0.66B | $3.73B | 17.76% |
| 2024-12-31 | $0.64B | $3.59B | 17.72% |
| 2024-09-30 | $0.63B | $3.45B | 18.36% |
| 2024-06-30 | $0.66B | $3.29B | 20.14% |
| 2024-03-31 | $0.67B | $3.16B | 21.14% |
| 2023-12-31 | $0.62B | $3.02B | 20.59% |
| 2023-09-30 | $0.61B | $2.88B | 21.13% |
| 2023-06-30 | $0.57B | $2.75B | 20.70% |
| 2023-03-31 | $0.55B | $2.64B | 20.79% |
| 2022-12-31 | $0.45B | $2.56B | 17.42% |
| 2022-09-30 | $0.39B | $2.53B | 15.35% |
| 2022-06-30 | $0.38B | $2.52B | 15.23% |
| 2022-03-31 | $0.31B | $2.49B | 12.51% |
| 2021-12-31 | $0.36B | $2.45B | 14.65% |
| 2021-09-30 | $0.27B | $2.39B | 11.17% |
| 2021-06-30 | $0.24B | $2.33B | 10.12% |
| 2021-03-31 | $0.24B | $2.27B | 10.40% |
| 2020-12-31 | $0.27B | $2.19B | 12.37% |
| 2020-09-30 | $0.19B | $2.13B | 8.82% |
| 2020-06-30 | $0.24B | $2.12B | 11.35% |
| 2020-03-31 | $0.26B | $2.11B | 12.28% |
| 2019-12-31 | $0.24B | $2.10B | 11.27% |
| 2019-09-30 | $0.38B | $2.07B | 18.56% |
| 2019-06-30 | $0.30B | $1.98B | 15.22% |
| 2019-03-31 | $0.27B | $1.92B | 14.14% |
| 2018-12-31 | $0.25B | $1.90B | 13.25% |
| 2018-09-30 | $0.24B | $1.90B | 12.48% |
| 2018-06-30 | $0.21B | $1.91B | 10.93% |
| 2018-03-31 | $0.15B | $1.91B | 7.89% |
| 2017-12-31 | $0.16B | $1.91B | 8.34% |
| 2017-09-30 | $0.18B | $1.87B | 9.42% |
| 2017-06-30 | $0.18B | $1.83B | 9.60% |
| 2017-03-31 | $0.19B | $1.78B | 10.46% |
| 2016-12-31 | $0.14B | $1.79B | 7.68% |
| 2016-09-30 | $0.16B | $1.83B | 8.55% |
| 2016-06-30 | $0.22B | $1.86B | 12.01% |
| 2016-03-31 | $0.30B | $1.90B | 15.88% |
| 2015-12-31 | $0.38B | $1.86B | 20.39% |
| 2015-09-30 | $0.38B | $1.80B | 21.34% |
| 2015-06-30 | $0.37B | $1.73B | 21.09% |
| 2015-03-31 | $0.36B | $1.67B | 21.55% |
| 2014-12-31 | $0.36B | $1.60B | 22.28% |
| 2014-09-30 | $0.37B | $1.53B | 23.94% |
| 2014-06-30 | $0.38B | $1.44B | 26.59% |
| 2014-03-31 | $0.35B | $1.35B | 26.02% |
| 2013-12-31 | $0.38B | $1.31B | 28.79% |
| 2013-09-30 | $0.35B | $1.27B | 27.14% |
| 2013-06-30 | $0.31B | $1.26B | 24.81% |
| 2013-03-31 | $0.31B | $1.21B | 25.68% |
| 2012-12-31 | $0.27B | $1.16B | 23.66% |
| 2012-09-30 | $0.30B | $1.09B | 27.60% |
| 2012-06-30 | $0.29B | $1.04B | 27.67% |
| 2012-03-31 | $0.29B | $1.05B | 27.43% |
| 2011-12-31 | $0.29B | $1.02B | 28.76% |
| 2011-09-30 | $0.26B | $1.05B | 24.67% |
| 2011-06-30 | $0.26B | $1.04B | 24.81% |
| 2011-03-31 | $0.25B | $1.01B | 24.20% |
| 2010-12-31 | $0.21B | $0.99B | 20.85% |
| 2010-09-30 | $0.03B | $0.94B | 3.61% |
| 2010-06-30 | $0.02B | $0.94B | 1.60% |
| 2010-03-31 | $0.02B | $0.93B | 2.26% |
| 2009-12-31 | $-0.21B | $0.90B | -23.21% |
| 2009-09-30 | $-0.06B | $0.95B | -5.93% |
| 2009-06-30 | $-0.08B | $0.98B | -7.69% |
| 2009-03-31 | $-0.10B | $1.03B | -9.24% |
| 2008-12-31 | $0.12B | $1.12B | 11.03% |
| 2008-09-30 | $0.06B | $1.13B | 5.49% |
| 2008-06-30 | $0.10B | $1.15B | 8.98% |
| 2008-03-31 | $0.12B | $1.13B | 10.40% |
| 2007-12-31 | $0.17B | $1.07B | 16.13% |
| 2007-09-30 | $0.33B | $1.01B | 32.87% |
| 2007-06-30 | $0.36B | $0.87B | 40.97% |
| 2007-03-31 | $0.34B | $0.74B | 46.43% |
| 2006-12-31 | $0.22B | $0.62B | 35.25% |
| 2006-09-30 | $0.09B | $0.53B | 17.89% |
| 2006-06-30 | $0.02B | $0.51B | 4.55% |
| 2006-03-31 | $0.00B | $0.50B | 0.20% |
| 2005-12-31 | $0.03B | $0.49B | 6.10% |
| 2005-09-30 | $0.03B | $0.49B | 6.11% |
| 2005-06-30 | $0.02B | $0.48B | 4.35% |
| 2005-03-31 | $0.02B | $0.48B | 3.57% |
| 2004-12-31 | $0.03B | $0.48B | 6.91% |
| 2004-09-30 | $0.03B | $0.47B | 6.84% |
| 2004-06-30 | $0.04B | $0.46B | 8.89% |
| 2004-03-31 | $0.05B | $0.45B | 11.95% |
| 2003-12-31 | $0.07B | $0.43B | 15.13% |
| 2003-09-30 | $0.07B | $0.41B | 16.34% |
| 2003-06-30 | $0.07B | $0.39B | 17.18% |
| 2003-03-31 | $0.08B | $0.37B | 20.30% |
| 2002-12-31 | $-0.01B | $0.35B | -2.57% |
| 2002-09-30 | $0.00B | $0.33B | 1.21% |
| 2002-06-30 | $0.03B | $0.31B | 9.02% |
| 2002-03-31 | $0.10B | $0.29B | 35.31% |
| 2001-12-31 | $0.20B | $0.24B | 84.99% |
| 2001-09-30 | $0.19B | $0.19B | 100.27% |
| 2001-06-30 | $0.16B | $0.14B | 111.91% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $11.109B | $3.811B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |